Figure 5: Representative joint-specific enriched biological pathway. | Nature Communications

Figure 5: Representative joint-specific enriched biological pathway.

From: Joint-specific DNA methylation and transcriptome signatures in rheumatoid arthritis identify distinct pathogenic processes

Figure 5

The ingenuity pathway analysis ‘role of JAK family kinases in IL-6-type cytokine signalling’ pathway is shown along with RA drug targets and anti-rheumatic drugs approved for use, in clinical trials or discontinued. Six RA drug targets were identified that have potential for differential responses between hips and knees, including IL-6, JAK1, JAK2, Tyk2, p38 MAPK and ERK1/2. Among the assigned RA drugs, tocilizumab and tofacitinib (labelled with *) that target IL-6 and JAKs, respectively, are currently approved for use in RA in the United States. The network was generated through the use of QIAGEN's Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City, www.qiagen.com/ingenuity)

Back to article page